-
1
-
-
0003594481
-
-
Bristol, UK, UK Renal Registry 2008
-
Ansell D, Feehally J, Fogarty D, Tomson C, Williams AJ, Warwick G: UK Renal Registry Report 2008, Bristol, UK, UK Renal Registry, 2008, pp 29-31
-
(2008)
UK Renal Registry Report
, pp. 29-31
-
-
Ansell, D.1
Feehally, J.2
Fogarty, D.3
Tomson, C.4
Williams, A.J.5
Warwick, G.6
-
2
-
-
33750127369
-
Current pharmacotherapy for the treatment of crescentic glomerulonephritis
-
Tam FWK: Current pharmacotherapy for the treatment of crescentic glomerulonephritis. Expert Opin Investig Drugs 15: 1353-1369, 2006
-
(2006)
Expert Opin Investig Drugs
, vol.15
, pp. 1353-1369
-
-
Tam, F.W.K.1
-
3
-
-
32844460938
-
Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans
-
Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J, Mangion J, Roberton-Lowe C, Marshall AJ, Petretto E, Hodges MD, Bhangal G, Patel SG, Sheehan-Rooney K, Duda M, Cook PR, Evans DJ, Domin J, Flint J, Boyle JJ, Pusey CD, Cook HT: Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439: 851-855, 2006
-
(2006)
Nature
, vol.439
, pp. 851-855
-
-
Aitman, T.J.1
Dong, R.2
Vyse, T.J.3
Norsworthy, P.J.4
Johnson, M.D.5
Smith, J.6
Mangion, J.7
Roberton-Lowe, C.8
Marshall, A.J.9
Petretto, E.10
Hodges, M.D.11
Bhangal, G.12
Patel, S.G.13
Sheehan-Rooney, K.14
Duda, M.15
Cook, P.R.16
Evans, D.J.17
Domin, J.18
Flint, J.19
Boyle, J.J.20
Pusey, C.D.21
Cook, H.T.22
more..
-
4
-
-
0037407787
-
Both Fcgamma receptor i and Fcgamma receptor III mediate disease in accelerated nephrotoxic nephritis
-
Tarzi RM, Davies KA, Claassens JW, Verbeek JS, Walport MJ, Cook HT: Both Fcgamma receptor I and Fcgamma receptor III mediate disease in accelerated nephrotoxic nephritis. Am J Pathol 162: 1677-1683, 2003
-
(2003)
Am J Pathol
, vol.162
, pp. 1677-1683
-
-
Tarzi, R.M.1
Davies, K.A.2
Claassens, J.W.3
Verbeek, J.S.4
Walport, M.J.5
Cook, H.T.6
-
5
-
-
2442618378
-
Fc receptor-mediated accumulation of macrophages in crescentic glomeru-lonephritis induced by anti-glomerular basement membrane antibody administration in WKY rats
-
Kovalenko P, Fujinaka H, Yoshida Y, Kawamura H, Qu Z, El-Shemi AG, Li H, Mat-suki A, Bilim V, Yaoita E, Abo T, Uchiyama M, Yamamoto T: Fc receptor-mediated accumulation of macrophages in crescentic glomeru-lonephritis induced by anti-glomerular basement membrane antibody administration in WKY rats. Int Immunol 16: 625-634, 2004
-
(2004)
Int Immunol
, vol.16
, pp. 625-634
-
-
Kovalenko, P.1
Fujinaka, H.2
Yoshida, Y.3
Kawamura, H.4
Qu, Z.5
El-Shemi, A.G.6
Li, H.7
Mat-Suki, A.8
Bilim, V.9
Yaoita, E.10
Abo, T.11
Uchiyama, M.12
Yamamoto, T.13
-
6
-
-
0031807018
-
The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutro-phils
-
Kiefer F, Brumell J, Al-Alawi N, Latour S, Cheng A, Veillette A, Grinstein S, Pawson T: The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutro-phils. Mol Cell Biol 18: 4209-4220, 1998
-
(1998)
Mol Cell Biol
, vol.18
, pp. 4209-4220
-
-
Kiefer, F.1
Brumell, J.2
Al-Alawi, N.3
Latour, S.4
Cheng, A.5
Veillette, A.6
Grinstein, S.7
Pawson, T.8
-
7
-
-
0032555744
-
Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide
-
Futterer K, Wong J, Grucza RA, Chan AC, Waksman G: Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol 281: 523-537, 1998
-
(1998)
J Mol Biol
, vol.281
, pp. 523-537
-
-
Futterer, K.1
Wong, J.2
Grucza, R.A.3
Chan, A.C.4
Waksman, G.5
-
8
-
-
34547849752
-
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor
-
Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E: Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 124: 244-257, 2007
-
(2007)
Clin Immunol
, vol.124
, pp. 244-257
-
-
Pine, P.R.1
Chang, B.2
Schoettler, N.3
Banquerigo, M.L.4
Wang, S.5
Lau, A.6
Zhao, F.7
Grossbard, E.B.8
Payan, D.G.9
Brahn, E.10
-
9
-
-
33751197936
-
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation
-
Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Gross-bard EB, Payan DG, Masuda ES: R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319: 998-1008, 2006
-
(2006)
J Pharmacol Exp Ther
, vol.319
, pp. 998-1008
-
-
Braselmann, S.1
Taylor, V.2
Zhao, H.3
Wang, S.4
Sylvain, C.5
Baluom, M.6
Qu, K.7
Herlaar, E.8
Lau, A.9
Young, C.10
Wong, B.R.11
Lovell, S.12
Sun, T.13
Park, G.14
Argade, A.15
Jurcevic, S.16
Pine, P.17
Singh, R.18
Gross-Bard, E.B.19
Payan, D.G.20
Masuda, E.S.21
more..
-
10
-
-
0033040126
-
Development of scarring and renal failure in a rat model of crescentic glomerulonephritis
-
Tam FWK, Smith J, Morel D, Karkar AM, Thompson EM, Cook HT, Pusey CD: Development of scarring and renal failure in a rat model of crescentic glomerulonephritis. Nephrol Dial Transplant 14: 1658-1666, 1999
-
(1999)
Nephrol Dial Transplant
, vol.14
, pp. 1658-1666
-
-
Tam, F.W.K.1
Smith, J.2
Morel, D.3
Karkar, A.M.4
Thompson, E.M.5
Cook, H.T.6
Pusey, C.D.7
-
11
-
-
34249897749
-
Genes expressed by both mesangial cells and bone marrow-derived cells underlie genetic susceptibility to crescentic glomerulonephritis in the rat
-
Smith J, Lai PC, Behmoaras J, Roufosse C, Bhangal G, McDaid JP, Aitman T, Tam FW, Pusey CD, Cook HT: Genes expressed by both mesangial cells and bone marrow-derived cells underlie genetic susceptibility to crescentic glomerulonephritis in the rat. J Am Soc Nephrol 18: 1816-1823, 2007
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 1816-1823
-
-
Smith, J.1
Lai, P.C.2
Behmoaras, J.3
Roufosse, C.4
Bhangal, G.5
McDaid, J.P.6
Aitman, T.7
Tam, F.W.8
Pusey, C.D.9
Cook, H.T.10
-
12
-
-
33846657540
-
Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis
-
Turner CM, Tam FW, Lai PC, Tarzi RM, Burn-stock G, Pusey CD, Cook HT, Unwin RJ: Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol Dial Transplant 22: 386-395, 2007
-
(2007)
Nephrol Dial Transplant
, vol.22
, pp. 386-395
-
-
Turner, C.M.1
Tam, F.W.2
Lai, P.C.3
Tarzi, R.M.4
Burn-Stock, G.5
Pusey, C.D.6
Cook, H.T.7
Unwin, R.J.8
-
13
-
-
34047205066
-
Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glo-merulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6
-
Sheryanna A, Bhangal G, McDaid J, Smith J, Manning A, Foxwell BM, Feldmann M, Cook HT, Pusey CD, Tam FWK: Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glo-merulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol 18: 1167-1179, 2007
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 1167-1179
-
-
Sheryanna, A.1
Bhangal, G.2
McDaid, J.3
Smith, J.4
Manning, A.5
Foxwell, B.M.6
Feldmann, M.7
Cook, H.T.8
Pusey, C.D.9
Tam, F.W.K.10
-
14
-
-
33645801826
-
Interleukin-11 reduces renal injury and glomerular NF-kappa B activity in murine experimental glomerulonephritis
-
Lai PC, Smith J, Bhangal G, Chaudhry KA, Chaudhry AN, Keith JC, Jr., Tam FW, Pusey CD, Cook HT: Interleukin-11 reduces renal injury and glomerular NF-kappa B activity in murine experimental glomerulonephritis. Nephron Exp Nephrol 101: e146-e154, 2005
-
(2005)
Nephron Exp Nephrol
, vol.101
-
-
Lai, P.C.1
Smith, J.2
Bhangal, G.3
Chaudhry, K.A.4
Chaudhry, A.N.5
Keith Jr., J.C.6
Tam, F.W.7
Pusey, C.D.8
Cook, H.T.9
-
15
-
-
17744382183
-
Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis
-
Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD: Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 67: 1812-1820, 2005
-
(2005)
Kidney Int
, vol.67
, pp. 1812-1820
-
-
Khan, S.B.1
Cook, H.T.2
Bhangal, G.3
Smith, J.4
Tam, F.W.5
Pusey, C.D.6
-
16
-
-
0034752532
-
Interleukin-11 attenuates nephrotoxic nephritis in Wistar Kyoto rats
-
Lai PC, Cook HT, Smith J, Keith JC, Jr., Pusey CD, Tam FWK: Interleukin-11 attenuates nephrotoxic nephritis in Wistar Kyoto rats. J Am Soc Nephrol 12: 2310-2320, 2001
-
(2001)
J Am Soc Nephrol
, vol.12
, pp. 2310-2320
-
-
Lai, P.C.1
Cook, H.T.2
Smith, J.3
Keith Jr., J.C.4
Pusey, C.D.5
Tam, F.W.K.6
-
17
-
-
0033964770
-
Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis
-
Tam FWK, Smith J, Agarwal S, Karkar AM, Morel D, Thompson EM, Pusey CD: Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. Nephron 84: 58-66, 2000
-
(2000)
Nephron
, vol.84
, pp. 58-66
-
-
Tam, F.W.K.1
Smith, J.2
Agarwal, S.3
Karkar, A.M.4
Morel, D.5
Thompson, E.M.6
Pusey, C.D.7
-
18
-
-
85058200770
-
Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glo-merular basement membrane glomerulone-phritis
-
Iyoda M, Shibata T, Kawaguchi M, Yamaoka T, Akizawa T: Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glo-merular basement membrane glomerulone-phritis. Kidney Int 75: 1060-1070, 2009
-
(2009)
Kidney Int
, vol.75
, pp. 1060-1070
-
-
Iyoda, M.1
Shibata, T.2
Kawaguchi, M.3
Yamaoka, T.4
Akizawa, T.5
-
19
-
-
43249129993
-
The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development
-
Kulathu Y, Hobeika E, Turchinovich G, Reth M: The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development. EMBO J 27: 1333-1344, 2008
-
(2008)
EMBO J
, vol.27
, pp. 1333-1344
-
-
Kulathu, Y.1
Hobeika, E.2
Turchinovich, G.3
Reth, M.4
-
20
-
-
34548481990
-
Syk-dependent actin dynamics regulate endocytic trafficking and processing of antigens internalized through the B-cell receptor
-
Le RD, Lankar D, Yuseff MI, Vascotto F, Yokoz-eki T, Faure-Andre G, Mougneau E, Glaichen-haus N, Manoury B, Bonnerot C, Lennon-Du-menil AM: Syk-dependent actin dynamics regulate endocytic trafficking and processing of antigens internalized through the B-cell receptor. Mol Biol Cell 18: 3451-3462, 2007
-
(2007)
Mol Biol Cell
, vol.18
, pp. 3451-3462
-
-
Le Rd Lankar, D.1
Yuseff, M.I.2
Vascotto, F.3
Yokoz-Eki, T.4
Faure-Andre, G.5
Mougneau, E.6
Glaichen-Haus, N.7
Manoury, B.8
Bonnerot, C.9
Lennon-Du-Menil, A.M.10
-
21
-
-
0030829551
-
A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages
-
Crowley MT, Costello PS, Fitzer-Attas CJ, Turner M, Meng F, Lowell C, Tybulewicz VL, DeFranco AL: A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages. J Exp Med 186: 1027-1039, 1997
-
(1997)
J Exp Med
, vol.186
, pp. 1027-1039
-
-
Crowley, M.T.1
Costello, P.S.2
Fitzer-Attas, C.J.3
Turner, M.4
Meng, F.5
Lowell, C.6
Tybulewicz, V.L.7
Defranco, A.L.8
-
22
-
-
24744449505
-
Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine)
-
Gevrey JC, Isaac BM, Cox D: Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine). J Immunol 175: 3737-3745, 2005
-
(2005)
J Immunol
, vol.175
, pp. 3737-3745
-
-
Gevrey, J.C.1
Isaac, B.M.2
Cox, D.3
-
23
-
-
55849114400
-
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
-
Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Gross-bard E: Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 58: 3309-3318, 2008
-
(2008)
Arthritis Rheum
, vol.58
, pp. 3309-3318
-
-
Weinblatt, M.E.1
Kavanaugh, A.2
Burgos-Vargas, R.3
Dikranian, A.H.4
Medrano-Ramirez, G.5
Morales-Torres, J.L.6
Murphy, F.T.7
Musser, T.K.8
Straniero, N.9
Vicente-Gonzales, A.V.10
Gross-Bard, E.11
-
24
-
-
0141991076
-
Monocyte chemoattractant protein (MCP)-1 production via functionally reconstituted Fcalpha receptor (CD89) on glomerular mesangial cells
-
Tsuge T, Suzuki Y, Shimokawa T, Horikoshi S, Okumura K, Ra C, Tomino Y: Monocyte chemoattractant protein (MCP)-1 production via functionally reconstituted Fcalpha receptor (CD89) on glomerular mesangial cells. Inflamm Res 52: 428-432, 2003
-
(2003)
Inflamm Res
, vol.52
, pp. 428-432
-
-
Tsuge, T.1
Suzuki, Y.2
Shimokawa, T.3
Horikoshi, S.4
Okumura, K.5
Ra, C.6
Tomino, Y.7
-
25
-
-
43949092440
-
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus
-
Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI: An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 58: 1433-1444, 2008
-
(2008)
Arthritis Rheum
, vol.58
, pp. 1433-1444
-
-
Bahjat, F.R.1
Pine, P.R.2
Reitsma, A.3
Cassafer, G.4
Baluom, M.5
Grillo, S.6
Chang, B.7
Zhao, F.F.8
Payan, D.G.9
Grossbard, E.B.10
Daikh, D.I.11
-
26
-
-
58149496650
-
Imatinib suppresses cryoglob-ulinemia and secondary membranoprolifera- tive glomerulonephritis
-
Iyoda M, Hudkins KL, Becker-Herman S, Wie-techa TA, Banas MC, Guo S, Meyer-Bahlburg A, Kowalewska J, Liu G, Ziegler SF, Rawlings DJ, Alpers CE: Imatinib suppresses cryoglob-ulinemia and secondary membranoprolifera-tive glomerulonephritis. J Am Soc Nephrol 20: 68-77, 2009
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 68-77
-
-
Iyoda, M.1
Hudkins, K.L.2
Becker-Herman, S.3
Wie-Techa, T.A.4
Banas, M.C.5
Guo, S.6
Meyer-Bahlburg, A.7
Kowalewska, J.8
Liu, G.9
Ziegler, S.F.10
Rawlings, D.J.11
Alpers, C.E.12
|